Download PDF
Semin Liver Dis 2012; 32(03): 245-255
DOI: 10.1055/s-0032-1323630
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Liver Transplantation in Delta Virus Infection

Bruno Roche
1   Assistance Publique-Hopitaux de Paris, Hopital Paul Brousse, Centre Hepato-Biliaire, Villejuif, France
2   INSERM, U785, Villejuif, France
3   Univ Paris-Sud, UMR-S785 Villejuif, France
,
Didier Samuel
1   Assistance Publique-Hopitaux de Paris, Hopital Paul Brousse, Centre Hepato-Biliaire, Villejuif, France
2   INSERM, U785, Villejuif, France
3   Univ Paris-Sud, UMR-S785 Villejuif, France
› Author Affiliations
Further Information

Publication History

Publication Date:
29 August 2012 (online)

    Permissions and Reprints

Abstract

Liver transplantation is the only therapy for patients with end-stage liver disease, hepatocellular carcinoma, or fulminant hepatitis due to hepatitis D virus (HDV) and hepatitis B virus (HBV) coinfection or superinfection. Patients chronically coinfected with HDV are less at risk of HBV recurrence and have a better survival rate than patients infected with HBV alone. Patients coinfected with HDV generally do not require pretransplant antiviral therapy. Rates of recurrent HBV-HDV infection are lower than 5% using low-dose intramuscular (IM) HBIg and antiviral prophylaxis in combination. Few studies have evaluated the possibility of using shorter-term HBIg (12–24 months) then switching to antiviral therapy. Although HBV replication can be controlled by potent HBV-polymerase inhibitors, reappearance of HBsAg and/or the persistence of HBV DNA in serum, liver, or peripheral blood mononuclear cells might have deleterious consequences in the setting of HBV-HDV coinfection as they may provide the biologic substrate to the reactivation of HDV. No effective antiviral drug is available for the treatment of graft infection with HDV.

Keywords

Hepatitis Delta liver transplantation - Hepatitis B immune globulins - HBV antiviral drugs
 

  • References

  • 1 Rizzetto M. Hepatitis D: thirty years after. J Hepatol 2009; 50 (5) 1043-1050
    CrossrefPubMedSearch in Google Scholar
  • 2 Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet 2011; 378 (9785) 73-85
    CrossrefPubMedSearch in Google Scholar
  • 3 Samuel D, Muller R, Alexander G , et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329 (25) 1842-1847
    CrossrefPubMedSearch in Google Scholar
  • 4 Grellier L, Mutimer D, Ahmed M , et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348 (9036) 1212-1215
    CrossrefPubMedSearch in Google Scholar
  • 5 Markowitz JS, Martin P, Conrad AJ , et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28 (2) 585-589
    CrossrefPubMedSearch in Google Scholar
  • 6 Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48 (2) 335-352
    CrossrefPubMedSearch in Google Scholar
  • 7 Fattovich G, Giustina G, Christensen E , et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000; 46 (3) 420-426
    CrossrefPubMedSearch in Google Scholar
  • 8 European Liver Transplant Registry. Homepage. Available at: http://www.eltr.org . Accessed February 29, 2012.
    PubMed
  • 9 Ottobrelli A, Marzano A, Smedile A , et al. Patterns of hepatitis delta virus reinfection and disease in liver transplantation. Gastroenterology 1991; 101 (6) 1649-1655
    PubMedSearch in Google Scholar
  • 10 Reynès M, Zignego L, Samuel D , et al. Graft hepatitis delta virus reinfection after orthotopic liver transplantation in HDV cirrhosis. Transplant Proc 1989; 21 (1 Pt 2) 2424-2425
    PubMedSearch in Google Scholar
  • 11 Rizzetto M, Macagno S, Chiaberge E , et al. Liver transplantation in hepatitis delta virus disease. Lancet 1987; 2 (8557) 469-471
    PubMedSearch in Google Scholar
  • 12 Samuel D, Zignego AL, Reynes M , et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology 1995; 21 (2) 333-339
    CrossrefPubMedSearch in Google Scholar
  • 13 Steinmüller T, Seehofer D, Rayes N , et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35 (6) 1528-1535
    CrossrefPubMedSearch in Google Scholar
  • 14 Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004; 10 (8) 968-974
    CrossrefPubMedSearch in Google Scholar
  • 15 David E, Rahier J, Pucci A , et al. Recurrence of hepatitis D (delta) in liver transplants: histopathological aspects. Gastroenterology 1993; 104 (4) 1122-1128
    PubMedSearch in Google Scholar
  • 16 Smedile A, Casey JL, Cote PJ , et al. Hepatitis D viremia following orthotopic liver transplantation involves a typical HDV virion with a hepatitis B surface antigen envelope. Hepatology 1998; 27 (6) 1723-1729
    CrossrefPubMedSearch in Google Scholar
  • 17 Mederacke I, Filmann N, Yurdaydin C , et al. Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. J Hepatol 2012; 56 (1) 115-122
    CrossrefPubMedSearch in Google Scholar
  • 18 Faria LC, Gigou M, Roque-Afonso AM , et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 2008; 134 (7) 1890-1899 , quiz 2155
    CrossrefPubMedSearch in Google Scholar
  • 19 Gane EJ, Angus PW, Strasser S , et al; Australasian Liver Transplant Study Group. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132 (3) 931-937
    CrossrefPubMedSearch in Google Scholar
  • 20 Degertekin B, Han SH, Keeffe EB , et al; NIH HBV-OLT Study Group. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant 2010; 10 (8) 1823-1833
    CrossrefPubMedSearch in Google Scholar
  • 21 Jiang L, Yan L, Li B , et al. Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin. Am J Transplant 2010; 10 (8) 1861-1869
    CrossrefPubMedSearch in Google Scholar
  • 22 Zheng S, Chen Y, Liang T , et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transpl 2006; 12 (2) 253-258
    CrossrefPubMedSearch in Google Scholar
  • 23 Chun J, Kim W, Kim BG , et al. High viremia, prolonged lamivudine therapy and recurrent hepatocellular carcinoma predict posttransplant hepatitis B recurrence. Am J Transplant 2010; 10 (7) 1649-1659
    CrossrefPubMedSearch in Google Scholar
  • 24 Coffin CS, Stock PG, Dove LM , et al. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. Am J Transplant 2010; 10 (5) 1268-1275
    CrossrefPubMedSearch in Google Scholar
  • 25 Marzano A, Gaia S, Ghisetti V , et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005; 11 (4) 402-409
    CrossrefPubMedSearch in Google Scholar
  • 26 Caccamo L, Agnelli F, Reggiani P , et al. Role of lamivudine in the posttransplant prophylaxis of chronic hepatitis B virus and hepatitis delta virus coinfection. Transplantation 2007; 83 (10) 1341-1344
    CrossrefPubMedSearch in Google Scholar
  • 27 Marzano A, Salizzoni M, Debernardi-Venon W , et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34 (6) 903-910
    CrossrefPubMedSearch in Google Scholar
  • 28 Perrillo RP, Wright T, Rakela J , et al; Lamivudine North American Transplant Group. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33 (2) 424-432
    CrossrefPubMedSearch in Google Scholar
  • 29 Lo CM, Cheung ST, Lai CL , et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001; 233 (2) 276-281
    CrossrefPubMedSearch in Google Scholar
  • 30 Malkan G, Cattral MS, Humar A , et al. Lamivudine for hepatitis B in liver transplantation: a single-center experience. Transplantation 2000; 69 (7) 1403-1407
    CrossrefPubMedSearch in Google Scholar
  • 31 Mutimer D, Dusheiko G, Barrett C , et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 2000; 70 (5) 809-815
    CrossrefPubMedSearch in Google Scholar
  • 32 Yoshida H, Kato T, Levi DM , et al. Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection. Clin Transplant 2007; 21 (2) 166-171
    CrossrefPubMedSearch in Google Scholar
  • 33 Schiff E, Lai CL, Hadziyannis S , et al; Adefovir Dipivoxil Study 45 International Investigators Group. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13 (3) 349-360
    CrossrefPubMedSearch in Google Scholar
  • 34 Fung J, Cheung C, Chan SC , et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011; 141 (4) 1212-1219
    CrossrefPubMedSearch in Google Scholar
  • 35 Dickson RC, Terrault NA, Ishitani M , et al. Protective antibody levels and dose requirements for IV 5% Nabi hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl 2006; 12 (1) 124-133
    CrossrefPubMedSearch in Google Scholar
  • 36 Buti M, Mas A, Prieto M , et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003; 38 (6) 811-817
    CrossrefPubMedSearch in Google Scholar
  • 37 Wong SN, Chu CJ, Wai CT , et al. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 2007; 13 (3) 374-381
    CrossrefPubMedSearch in Google Scholar
  • 38 Han SH, Ofman J, Holt C , et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6 (6) 741-748
    CrossrefPubMedSearch in Google Scholar
  • 39 Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP ; Böker KHW. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34 (6) 895-902
    CrossrefPubMedSearch in Google Scholar
  • 40 Neff GW, O'brien CB, Nery J , et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 2004; 10 (11) 1372-1378
    CrossrefPubMedSearch in Google Scholar
  • 41 Anselmo DM, Ghobrial RM, Jung LC , et al. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg 2002; 235 (5) 611-619 , discussion 619–620
    CrossrefPubMedSearch in Google Scholar
  • 42 Xi ZF, Xia Q, Zhang JJ , et al. The role of entecavir in preventing hepatitis B recurrence after liver transplantation. J Dig Dis 2009; 10 (4) 321-327
    CrossrefPubMedSearch in Google Scholar
  • 43 Yi NJ, Suh KS, Cho JY , et al. Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2007; 13 (3) 451-458
    CrossrefPubMedSearch in Google Scholar
  • 44 Hooman N, Rifai K, Hadem J , et al. Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl 2008; 14 (4) 435-442
    CrossrefPubMedSearch in Google Scholar
  • 45 Yahyazadeh A, Beckebaum S, Cicinnati V , et al. Efficacy and safety of subcutaneous human HBV-immunoglobulin (Zutectra) in liver transplantation: an open, prospective, single-arm phase III study. Transpl Int 2011; 24 (5) 441-450
    CrossrefPubMedSearch in Google Scholar
  • 46 Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review. Liver Transpl 2011; 17 (10) 1176-1190
    CrossrefPubMedSearch in Google Scholar
  • 47 Rao W, Wu X, Xiu D. Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis. Transpl Int 2009; 22 (4) 387-394
    CrossrefPubMedSearch in Google Scholar
  • 48 Katz LH, Paul M, Guy DG, Tur-Kaspa R. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis. Transpl Infect Dis 2010; 12 (4) 292-308
    CrossrefPubMedSearch in Google Scholar
  • 49 Loomba R, Rowley AK, Wesley R , et al. Hepatitis B immunoglobulin and lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol 2008; 6 (6) 696-700
    CrossrefPubMedSearch in Google Scholar
  • 50 Sánchez-Fueyo A, Rimola A, Grande L , et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31 (2) 496-501
    CrossrefPubMedSearch in Google Scholar
  • 51 Angelico M, Di Paolo D, Trinito MO , et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002; 35 (1) 176-181
    CrossrefPubMedSearch in Google Scholar
  • 52 Bienzle U, Günther M, Neuhaus R , et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003; 38 (4) 811-819
    CrossrefPubMedSearch in Google Scholar
  • 53 Albeniz Arbizu E, Barcena Marugan R, Oton Nieto E , et al. Prophylaxis of recurrent hepatitis B virus by vaccination after liver transplant: preliminary results. Transplant Proc 2003; 35 (5) 1848-1849
    CrossrefPubMedSearch in Google Scholar
  • 54 Lo CM, Liu CL, Chan SC, Lau GK, Fan ST. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol 2005; 43 (2) 283-287
    CrossrefPubMedSearch in Google Scholar
  • 55 Rosenau J, Hooman N, Hadem J , et al. Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transpl 2007; 13 (3) 367-373
    CrossrefPubMedSearch in Google Scholar
  • 56 Dodson SF, de Vera ME, Bonham CA, Geller DA, Rakela J, Fung JJ. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000; 6 (4) 434-439
    CrossrefPubMedSearch in Google Scholar
  • 57 Naoumov NV, Lopes AR, Burra P , et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001; 34 (6) 888-894
    CrossrefPubMedSearch in Google Scholar
  • 58 Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008; 48 (5) 1460-1466
    CrossrefPubMedSearch in Google Scholar
  • 59 Saab S, Desai S, Tsaoi D , et al. Posttransplantation hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy. Am J Transplant 2011; 11 (3) 511-517
    CrossrefPubMedSearch in Google Scholar
  • 60 Lenci I, Tisone G, Di Paolo D , et al. Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. J Hepatol 2011; 55 (3) 587-593
    CrossrefPubMedSearch in Google Scholar
  • 61 Roche B, Feray C, Gigou M , et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003; 38 (1) 86-95
    CrossrefPubMedSearch in Google Scholar
  • 62 Hussain M, Soldevila-Pico C, Emre S, Luketic V, Lok AS ; NIH HBV-OLT Study Group. Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation. Liver Transpl 2007; 13 (8) 1137-1144
    CrossrefPubMedSearch in Google Scholar